



**BUILDING AN EVIDENCE BASE FOR A
COLLABORATIVE MEDICATION THERAPY
MANAGEMENT MODEL FOR CHRONIC DISEASES IN
MALAYSIA: PERSPECTIVES OF HEALTHCARE
STAKEHOLDERS**

BY

NAEEM MUBARAK

**A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Pharmaceutical Sciences
(Pharmacy Practice)**

**Kulliyyah of Pharmacy
International Islamic University Malaysia**

AUGUST 2019

ABSTRACT

Ageing populations and burden of chronic diseases affect economies, resources, and most importantly quality of patient care. Generally, in chronic diseases, patients take multiple drugs life long and there is a need to better manage their medicine. Collaboration among the healthcare providers in chronic diseases is required for effective medicine management to improve the outcomes of drug therapy. In developed countries, collaborative working of the community pharmacist and general practitioners to manage medicines in chronic disease have been extensively cited as beneficial. However, in Malaysia, there exists least collaboration between community pharmacist and general practitioner. The aim of this mix method study was to build an evidence base for a collaborative medication therapy management model by engaging community pharmacists and general practitioners in a collaborative practice for chronic diseases with a special focus on asthma in three phases.

Phase one of this study quantified the impact of collaborative practice between community pharmacist and general practitioner on various clinical, humanistic and economical outcomes in asthma in the form of a systematic review and meta-analysis. This served as a base for the next phase.

Phase two deployed Delphi technique (a consensus based method) to gauge level of agreement among different healthcare stakeholders on collaborative working of community pharmacist and general practitioners. Twenty-nine experts (mainly on strategic posts) were recruited from all over Malaysia, representing i.e., community pharmacists (n=10), general practitioners (n=11) and nurses (n=8), to constitute a panel of experts. An online questionnaire consisted of 132 items, was drafted, validated and administered to the experts. Median, interquartile range and intra-class correlation coefficient were computed to appraise degree of consensus or dissensus, among the experts for the possibilities and different aspects of a collaborative medicine management model for chronic diseases. The results were assembled in the form of recommendations.

Phase three of the study began with the aim to further enrich data obtained in the phase two, based on axiom of triangulation, through in-depth semi-structured interviews. Twelve experts (from the same expert panel) were interviewed to size up views, perception and experiences of experts about various aspects of collaboration. Themes were identified using a constant comparison approach based on grounded theory, while theoretical saturation directed the data collection. Result of this phase confirmed the data acquired in phase-2 and explored the collaboration possibilities in details and covered various barriers, diseases, modes of funding for the service, and the feasibility of establishing the collaborative medicine management model in Malaysia.

Data generated in three phases of research are an original contribution to the evidence base and provided a frame work to guide the future health care policy to switch to a collaborative medicine management model and recommends future research to evaluate its related outcomes using a randomized control trial.

Key words: community pharmacist, general practitioner, medicine management, medication therapy management, chronic disease, asthma, collaborative care, shared care, team based care, Delphi method, perception, barriers, qualitative inquiry, Malaysia.

خلاصة البحث

رعاية جودة ذلك من والأهم ، والموارد الاقتصادية على تؤثر المزممة الأمراض وعبء السكان شيخوخة لإدارة حاجة وهناك الحياة مدى متعددة عقاقير المرضى يأخذ ، المزممة الأمراض في ، عام بشكل .المرضى الإدارة أجل من المزممة الأمراض في الصحية الرعاية مقدمي بين تعاون مطلوب .أفضل بشكل أدويتهم بالعمل واسع نطاق على الاستشهاد تم ، المتقدمة البلدان في .الدوائي العلاج نتائج لتحسين للطب الفعالة من الأولى المرحلة حددت .المزممة الأمراض في الأدوية لإدارة العاميين والممارسين المجتمع لصيادلة التعاوني السريرية النتائج مختلف على العام والممارس المجتمع صيدلي بين التعاونية الممارسة تأثير الدراسة هذه القادمة للمرحلة قاعدة بمثابة هذا .تلوي وتحليل منهجية مراجعة شكل في الربو في والاقتصادية والإنسانية أصحاب مختلف بين الاتفاق مستوى لقياس (الإجماع على تعتمد طريقة) دلفي تقنية الثانية المرحلة نشرت وعشرين تسعة تعيين تم .العاميين والممارسين المجتمع لصيادلة التعاوني العمل على الصحية الرعاية في المصلحة (10 = ن) المجتمع صيادلة أي يمثلون ، ماليزيا أنحاء جميع من (الاستراتيجية الوظائف في أساسا) خبيرا عبر الاستبيان يتكون .الخبراء من لجنة لتشكيل ، (8 = ن) والمرضات (11 = ن) العاميين والممارسين مجموعة ، متوسط حساب تم. للخبراء وإدارته صحته من والتحقق صياغته وتمت ، بندا 132 من الإنترنت الخبراء بين ، الإختلاف أو الإجماع من درجة لتقييم الطبقة داخل الارتباط ومعامل interquartile شكل في النتائج تجميع تم .المزممة للأمراض التعاوني الدواء إدارة لنموذج المختلفة والجوانب لإمكانيات المرحلة في عليها الحصول تم التي البيانات إثراء زيادة بهدف الدراسة من الثالثة المرحلة بدأت .توصيات اثني مع مقابلات وأجريت .متعمقة منظمة شبه مقابلات خلال من ، التثليث بديهية على بناءً ، الثانية جوانب مختلف حول الخبراء وخبرات وتصورات نظر وجهات لتكبير (نفسه الخبراء فريق من) خبيرا عشر التشعب وجه حين في ، متأصلة نظرية على يعتمد ثابت مقارنة نهج باستخدام السمات تحديد تم .التعاون الثانية المرحلة في عليها الحصول تم التي البيانات المرحلة هذه نتيجة أكدت .البيانات جمع النظري للخدمة التمويل وأساليب والأمراض الحواجز مختلف وغطت التفاصيل في التعاون إمكانيات واستكشفت ماليزيا في التعاونية الأدوية لإدارة نموذج إنشاء وجدوى ، ربو ، مزممن مرض ، دوائي علاج إدارة ، دواء إدارة ، عام طبيب ، مجتمع صيدلي :المفتاحية الكلمات .ماليزيا ، نوعي تحقيق ، حواجز ، إدراك ، دلفي طريقة ، جماعية رعاية ، مشتركة رعاية ، تعاونية رعاية

APPROVAL PAGE

The thesis of Naeem Mubarak has been approved by the following:

Che Suraya Mohd Zin
Supervisor

Ernieda Md Hatah
Co-Supervisor

Mohd Aznan Md Aris
Co-Supervisor

Asrul Akmal Shafie
Co-Supervisor

Norny Syafinaz Ab. Rahman
Internal Examiner

Mohamed Azmi bin Ahmad Hassali
External Examiner

Mohamed Izham bin Mohamed Ibrahim
External Examiner

Zarina bt Zainuddin
Chairman

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Naeem Mubarak

Signature: *Naeem Mubarak.*

Date: 19-08-2019

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**BUILDING AN EVIDENCE BASE FOR A COLLABORATIVE
MEDICATION THERAPY MANAGEMENT MODEL FOR
CHRONIC DISEASES IN MALAYSIA: PERSPECTIVES OF
HEALTHCARE STAKEHOLDERS.**

I declare that the copyright holders of this thesis are jointly owned by the student
and IIUM.

Copyright © 2019 Naeem Mubarak and International Islamic University Malaysia. All rights
reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system,
or transmitted, in any form or by any means, electronic, mechanical, photocopying,
recording or otherwise without prior written permission of the copyright holder
except as provided below

1. Any material contained in or derived from this unpublished research
may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print
or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system
and supply copies of this unpublished research if requested by other
universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM
Intellectual Property Right and Commercialization policy.

Affirmed by Naeem Mubarak

Signature: Naeem Mubarak

Date: 19-08-2019

ACKNOWLEDGEMENT

Spectacular accomplishments are never possible without spectacular preparations. During the whole course of writing this thesis, this statement became my mantra. Now, as I look back, I savvy that this statement fully portrays my doctoral journey, and I would like to express my humble gratitude for the people who helped me prepare for this accomplishment.

First, all praises and glory to Allah subhanahu wa ta'ala, Who has always provided unlimited support for all of my endeavors. I owe a huge debt of gratitude to my dissertation chairperson, Assoc. Prof. Che Suraya Mohd Zin, whose advice and guidance has enabled me to carry out this arduous study. Honestly, words are not enough to thank you for the countless emails, pundit and prompt feedback, and words of encouragement throughout this journey. I never would have finished so quickly without your willingness to keep reading and providing feedback (especially in the summer!). Your exceptional mentorship has trained me to educate the future generation scholar in the field of pharmacy practice in Pakistan. I am also highly indebted to my co-supervisors, Dr Ernieda M Hatah, Assoc. Prof. Mohd Aznan Md Aris and Assoc. Prof. Asrul Akmal Shafie for the scholarly input to refine various ideas of the research project, especially Dr Ernieda, who has been a source of immense learning. Out with my supervisory team, I would like to thank all the members of expert panel for their valuable time, insightful comments, and feedback to complete all survey rounds and in-depth interviews.

With love and eternal appreciation, I thank my family to whom I owe a great deal. My great father, Mubarak Ali, who has the dream to put his kids in the intellectual pursuit. My mother, Mussarat Mubarak, who is herself a teacher, whose fathomless prayers & tasbeehat enabled me to overcome the obstacles of this path. My better half, Sabba, for always being there through thick and thin to motivate me to follow a set routine and helped me in all possible ways to do the thesis on time. My maternal aunt, Ms Anwar Sultana for her motherly prayers and care.

With due reverence, immense gratitude and appreciation is extended to Mr Asad Ahmad Khan, Company Secretary, Lahore Medical & Dental College, for the morale, financial and emotional support throughout these years and for always trusting in me.

A huge heartfelt thanks to Mr Anjum Shaheen for his time and efforts to accompany me for interviews of the experts in various parts of Malaysia. Without you, this task would never have been accomplished on time.

Last but certainly not least, a special thanks to world renowned Delphi expert, Dr Chitu Okali, Associate Professor, Concordia University, Canada, for guiding me throughout the Delphi survey. I would also like to thank, Professor Dr Khalid Ahmad, Punjab University, Lahore, Pakistan, for the advice on various statistical operations.

TABLE OF CONTENTS

Abstract.....	ii
Abstract in Arabic.....	iii
Approval Page.....	iv
Declaration.....	v
Copyright Page.....	vi
Acknowledgement.....	vii
Table of Contents.....	viii
List of Tables.....	xv
List of Figures.....	xvii
Abbreviations.....	xix
CHAPTER ONE: INTRODUCTION.....	1
1.1 Chapter Introduction.....	1
1.2 Background of the Problem.....	2
1.2.1 Global Burden of Chronic Diseases.....	2
1.2.2 Medicines and Chronic Diseases.....	4
1.2.2.1 Medicine Use in Chronic Diseases.....	4
1.2.2.2 Medication Errors and Adverse Drug Reactions.....	4
1.2.2.3 Poor Adherence to Medications; a Real Challenge in Chronic Diseases.....	5
1.2.2.4 Lack of Patient Education.....	6
1.2.2.5 Ramifications of Lack of Monitoring System; Establishing the Need of Persistent Monitoring on the Medicine Use Process.....	7
1.2.3 Need to Optimally Manage Medicine.....	8
1.3 Malaysia.....	9
1.3.1 Malaysian Healthcare System.....	10
1.3.1.1 Public Sector.....	11
1.3.1.1.1 Primary, Secondary and Tertiary Care.....	11
1.3.1.1.2 Pharmacist and Pharmacy Practice in Public Sector.....	13
1.3.1.1.3 Collaboration between Pharmacist and General Practitioner in Public Sector.....	15
1.3.1.2 Private Sector.....	16
1.3.1.2.1 Primary, Secondary and Tertiary Care.....	16
1.3.1.2.2 General Practitioner.....	17
1.3.1.2.3 Community Pharmacist and Pharmacy Practice in Private Sector.....	18
1.3.1.2.4 Collaboration between Community Pharmacist and General Practitioner in Private Sector.....	19
1.3.1.3 Chronic Disease Burden in Malaysia.....	20
1.3.1.4 Soaring Healthcare Needs of an Aging Population.....	20
1.3.1.5 Escalating Expenditure on Medicine.....	21
1.3.1.6 Problems in Primary Healthcare System.....	22

1.3.1.6.1 Suboptimal Management and Poor Control of Chronic Diseases.....	22
1.3.1.6.2 Inadequate Response to Chronic Diseases.....	22
1.3.1.6.3 Insufficiency of Inter-professional Collaboration.....	24
1.3.1.6.4 Lack of Adherence and Educational Support for Patients.....	25
1.3.1.6.5 Absence of Prescription Review System in Private Practice	26
1.3.1.6.6 Inappropriate Prescribing and Prescribing Errors.....	26
1.3.1.6.7 Dispensing Separation and Underutilized Community Pharmacists	27
1.3.1.6.8 Compromised Quality in Chronic Care	28
1.4 STATEMENT OF THE PROBLEM; OVERALL SCENARIO	29
1.5 RESEARCH GAP	30
1.6 RESEARCH QUESTIONS	36
1.7 RESEARCH OBJECTIVES.....	38
1.8 NATURE OF THE STUDY.....	38
1.9 ORGANIZATION OF THESIS	39
1.9.1 Chapter-1.....	39
1.9.2 Chapter-2.....	40
1.9.3 Chapter-3.....	40
1.9.4 Chapter-4.....	40
1.9.5 Chapter-5.....	41
1.9.6 Chapter-6.....	41
1.10 Significance of the Study.....	43
CHAPTER TWO: LITERATURE REVIEW.....	48
2.1 Chapter Introduction.....	48
2.2 Concept of Collaboration in Healthcare	50
2.2.1 Collaboration.....	50
2.2.1.1 Collaboration in Healthcare System.....	50
2.2.1.2 Need of Collaboration in Chronic Diseases	51
2.2.1.3 Collaboration, Essence of an Effective Chronic Care: A Who's Rhetoric	52
2.3 Collaboration Between Community Pharmacist and General Practitioner	53
2.3.1 Historical Panorama.....	53
2.3.2 Facets of Pharmacy Profession	54
2.3.2.1 Hospital Pharmacy.....	55
2.3.2.2 Community Pharmacy	55
2.3.3 Need of Pharmaceutical Care in Chronic Diseases.....	56
2.3.3.1 Concept of Pharmaceutical Care as the Point of Collaboration between Community Pharmacist and General Practitioner.....	58
2.3.3.2 Pharmaceutical Care; from Philosophy to Practice	58
2.3.3.3 Collaboration between Community Pharmacist and General Pharmacist; Practices in Developed Countries	60
2.3.3.3.1 United States of America (USA)	62
2.3.3.3.2 United Kingdom (UK).....	66

2.3.3.3.3 Canada	70
2.3.3.3.4 Australia.....	72
2.3.3.3.5 New Zealand.....	76
2.3.3.3.6 Europe.....	78
2.3.3.4 Collaboration between Community Pharmacist and General Practitioner in Low- and Middle-Income Countries.....	91
2.3.3.5 Community Pharmacist and General Practitioner Collaboration in East Asia and South-East Asia.....	91
2.3.4 Impact of Collaborative Practice between Community Pharmacist and General Practitioner	95

**CHAPTER THREE: A SYSTEMATIC REVIEW AND META-ANALYSIS
OF THE IMPACT OF COLLABORATIVE PRACTICE BETWEEN
COMMUNITY PHARMACIST AND GENERAL PRACTITIONER ON
ASTHMA MANAGEMENT..... 101**

3.1 Chapter Introduction.....	101
3.2 Introduction	102
3.2.1 Asthma in Malaysia	102
3.2.2 Involvement of General Practitioners in Management of Asthma.....	103
3.2.3 Involvement of Community Pharmacist in Management of Asthma.....	104
3.2.4 Collaboration between Community Pharmacist and General Practitioner	105
3.3 Problem Statement.....	107
3.3.1 Management of Asthma.....	107
3.3.2 Economic Burden.....	107
3.3.3 Lack of Adherence and Patient Education.....	108
3.4 Research Question	109
3.5 Systematic Review and Meta-Analysis	109
3.6 Rationale.....	110
3.7 Methods	112
3.7.1 Protocol.....	112
3.7.2 Search Strategy	115
3.7.3 Study Selection	115
3.7.4 Data Extraction	117
3.7.5 Outcome of Interest.....	117
3.7.6 Collaboration Scale.....	118
3.7.7 Data Analysis	118
3.7.7.1 Risk of Bias (RoB) Assessment	118
3.7.7.2 Procedure of Meta-analysis	119
3.7.7.3 Forest Plot.....	120
3.7.7.4 Heterogeneity	122
3.7.7.5 Effect Size (ES)	124
3.7.7.6 Interpretation of Effect Size	125
3.8 Results	126
3.8.1 Appraisal of Risk of Bias.....	129
3.8.2 Impact of the Collaborative Interventions	131

3.8.3 Evidence Base through Narrative Synthesis	131
3.8.3.1 Clinical Outcomes	145
3.8.3.2 Humanistic Outcomes	146
3.8.3.3 Economic Outcomes.....	147
3.8.4 Evidence Base through Meta-Analysis.....	148
3.9 DISCUSSION.....	166
3.10 LIMITATIONS	170
3.10.1 Difficulty in Meta-analysis	170
3.11 FUTURE RESEARCH.....	172
3.12 CONCLUSION	173

CHAPTER FOUR: CONSENSUS AMONG HEALTHCARE STAKEHOLDERS ON A COLLABORATIVE MEDICATION THERAPY MANAGEMENT MODEL FOR CHRONIC DISEASES IN MALAYSIA; A DELPHI STUDY..... 175

4.1 CHAPTER INTRODUCTION.....	175
4.2 BACKGROUND	176
4.2.1 Consensus Methods	176
4.2.1.1 Nominal Group Technique.....	178
4.2.1.2 Delphi Method.....	178
4.2.1.2.1 History	178
4.2.1.2.2 Types.....	180
4.2.1.2.3 Philosophical Basis of Delphi.....	181
4.2.1.2.4 Key Characteristics of the Delphi Process.....	181
4.2.1.3 Statistical Analysis and Results.....	186
4.2.1.4 Validity and Reliability	186
4.3 RESEARCH OBJECTIVES.....	186
4.4 METHODS	187
4.4.1 Modified e-Delphi Survey	187
4.4.1.1 Reasons to Choose Delphi Method	189
4.4.1.2 Advantages of Modified e-Delphi	190
4.4.2 Experts	191
4.4.2.1 Expert Selection Identification and Recruitment	191
4.4.2.2 Ensuring Optimal Response Rate	196
4.4.3 Survey Instrument.....	196
4.4.3.1 Survey Development through Literature Review (Survey on Word-Document).....	196
4.4.3.2 Survey Instrument Validation.....	197
4.4.3.3 Web version of the Survey (Online Version)	199
4.4.3.3.1 QuestionPro®	199
4.4.3.3.2 Reasons to Choose Question Pro® as a Survey Tool.....	199
4.4.3.3.3 Final Check on the Online Version.....	200
4.4.3.3.4 Sections of the Survey Instrument.....	200
4.4.3.4 Instrument administration.....	207
4.4.4 Defining Consensus	207
4.4.5 2nd Round's Survey Instrument	209
4.4.6 Ethical Approval	209
4.4.7 Data Analysis	210

4.4.7.1	Quantitative data and statistical analysis	210
4.4.7.1.1	Rating statements	210
4.4.7.1.2	Ranking statements	210
4.4.7.1.3	Intra-class Correlation Coefficient (ICC)	211
4.4.7.1.4	Stability in response	212
4.4.7.2	Qualitative data and narrative synthesis	212
4.4.8	Planning to Overcome the Limitations of Delphi	212
4.5	Results	213
4.5.1	Experts	213
4.5.1.1	Response and Completion Rate	213
4.5.1.2	Demographics of Expert Panel	214
4.5.2	Survey Instrument	219
4.5.2.1	Validity of the Instrument	219
4.5.2.1.1	Face Validity	219
4.5.2.1.2	Content Validity	219
4.5.3	Delphi Rounds	219
4.5.3.1	Theme-1	221
4.5.3.2	Theme-2	222
4.5.3.3	Theme-3	222
4.5.3.4	Theme-4	223
4.5.3.5	Theme-5	223
4.5.3.6	Theme-6	224
4.5.3.7	Theme-7	224
4.5.3.8	Theme-8	224
4.5.3.9	Theme-9	225
4.5.3.10	Theme-10	225
4.5.3.11	Theme-11	226
4.5.4	Qualitative analysis	243
4.5.5	Stability of response between two rounds (Wilcoxon signed rank test)	246
4.6	Discussion	246
4.6.1	Recommendations	251
4.6.1.1	For the Ministry of Health	251
4.6.1.2	For Community pharmacists' leadership	252
4.6.1.3	For General Practitioners' leadership	253
4.6.1.4	For Ministry of education	253
4.6.2	Theoretical framework of CMTM	253
4.7	Conclusion	254

CHAPTER FIVE: UNDERSTANDING PERSPECTIVES OF HEALTHCARE STAKEHOLDERS ON COLLABORATION BETWEEN COMMUNITY PHARMACIST (CP) AND GENERAL PRACTITIONER (GP) FOR A COLLABORATIVE MEDICATION THERAPY MANAGEMENT (CMTM) MODEL FOR CHRONIC DISEASES IN MALAYSIA.....	256
5.1 CHAPTER INTRODUCTION.....	256
5.2 LINK WITH THE PREVIOUS CHAPTERS	257
5.3 RESEARCH METHODS (QUALITATIVE VS QUANTITATIVE).....	257
5.3.1 Approaches in Qualitative Research.....	258

5.3.2 Rationale to Use the Qualitative Method (Face-to-Face Interviews)	260
5.4 RESEARCH QUESTION	261
5.5 RESEARCH OBJECTIVES	262
5.6 METHODS	262
5.6.1 Experts Identification and Recruitment	262
5.6.1.1 Selection Criteria	262
5.6.2 Semi-structured Personal Interviews	263
5.6.2.1 Interview Guide	263
5.6.2.2 Interview Settings	264
5.6.2.3 Interview Process	265
5.6.3 Data Management and Analysis	265
5.6.3.1 Transcription, Coding and Theme Generation	266
5.6.3.2 Trustworthiness and Credibility	268
5.6.3.3 Theoretical Saturation	268
5.6.4 Ethics	269
5.6.4.1 Anonymity and Confidentiality	269
5.6.4.2 Informed Consent	269
5.6.4.3 Ethical Approval	269
5.7 Results	269
5.7.1 Demographics of the Interview Key Informants	270
5.7.2 Themes	274
5.7.2.1 Theme 1-Developed Countries and Malaysia; a Comparison	275
5.7.2.1.1 Developed Countries	276
5.7.2.1.2 Malaysia	277
5.7.2.2 Theme 2-Current Situation in Malaysia	278
5.7.2.2.1 Current Practice GP	279
5.7.2.2.2 Current Practice CP	280
5.7.2.2.3 CP as an Untapped National Resource	280
5.7.2.2.4 CP's Perception or Disappointment	280
5.7.2.2.5 Current Law or Legislation	281
5.7.2.2.6 Prescription Review	281
5.7.2.2.7 Single Care Provider	282
5.7.2.2.8 Barriers in Collaboration	282
5.7.2.3 Theme 3-Collaboration of Community Pharmacist and General Practitioner in Malaysia	293
5.7.2.3.1 Why Should They Collaborate?	294
5.7.2.3.2 Need of Collaboration	295
5.7.2.3.3 Advantages of Collaboration	295
5.7.2.3.4 Against Collaboration	299
5.7.2.3.5 If No Collaboration? (Disadvantages of No Collaboration)	299
5.7.2.4 Theme 4-Dispensing Separation an Old Heated Debate; Implication on Collaboration	299
5.7.2.4.1 Against Dispensing Separation	300
5.7.2.4.2 Favours Dispensing Separation	301
5.7.2.5 Theme 5-Way Forward Towards the Collaboration of Community Pharmacist and General Practitioner in	

Malaysia for Collaborative Medication Therapy Management Model.....	302
5.7.2.5.1 How Could Collaboration be Achieved?	304
5.7.2.5.2 Taking First Practical Step.....	305
5.7.2.5.3 Law and Policy	305
5.7.2.5.4 Regulatory Aspects	306
5.7.2.5.5 Agreement.....	307
5.7.2.5.6 Communication.....	309
5.7.2.5.7 Financial Aspects of Collaborative Medication Therapy Management Model.....	310
5.7.2.5.8 How to Influence the Political Will	313
5.7.2.5.9 Inter-professional Education.....	313
5.7.2.5.10 Need for Continuous Professional Development.....	314
5.7.2.5.11 System.....	316
5.7.2.5.12 Solutions	319
5.7.3 Comparison of Current Situation and Way Forward for Collaborative Medication Therapy Management	322
5.8 Discussion.....	323
5.8.1 Concept Mapping of Way Forward towards Collaborative Medication Therapy Management Model in Malaysia	329
5.9 Conclusion	330
CHAPTER SIX: CONCLUSION.....	332
6.1 STRENGTHS	332
6.2 LIMITATIONS	332
6.3 RECOMMENDATIONS	334
6.4 TAKE HOME MESSAGE.....	335
REFERENCES.....	339
PUBLICATIONS AND PRESENTATIONS.....	375
APPENDIX I.....	376
APPENDIX II.....	395
APPENDIX III	404
APPENDIX IV	410
APPENDIX V.....	417
APPENDIX VI	421
APPENDIX VII.....	435
APPENDIX VIII	441
GLOSSARY.....	455
INDEX.....	458

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
Table 1. 1	Healthcare work force and facilities in Malaysia	11
Table 1. 2	Summary of the organization of thesis linked with research questions and objectives of the study	42
Table 2. 1	Community pharmacist and general practitioner collaborative practices in developed countries	89
Table 2.2	Community pharmacist and general practitioner collaboration practices in East Asia	94
Table 2. 3	Various systematic reviews or overviews to appraise the impact of pharmaceutical care provided by community pharmacists in collaboration with general practitioners	97
Table 3. 1	Detailed exclusion inclusion criterion as per Population, Intervention, Comparator, Outcome, Timings and Settings (PICO-TS)	113
Table 3. 2	Interpretation of forest plot	122
Table 3. 3	Summary of the characteristics of the included studies	133
Table 3. 4	Overall meta-analysis	149
Table 3. 5	Subgroup meta-analysis results	160
Table 3. 6	Conclusion of outcomes based on the effect size	164
Table 4. 1	Criteria for experts' selection	193
Table 4. 2	Describes these limitations and how we planned to tackle them	213
Table 4. 3	Response and completion rate of experts in 1st and 2nd round	214
Table 4. 4	Demographics of Delphi experts	217
Table 4. 5	Field/ area of expertise and professional associations or affiliations of experts	218
Table 4. 6	Consensus among experts in both rounds (based on percentage sum of agree and strongly agree) and stability in response of experts between rounds (based on Wilcoxon signed rank test)	227

Table 4. 7	Consensus among experts in both rounds for ranking statements (based on median, IQR and Kendall's W) and stability in response of experts between rounds (based on Wilcoxon signed rank test) for mean rank and priority order	238
Table 4. 8	Intra-class correlation coefficient (ICC) test results	241
Table 4. 9	Statements over which consensus was not achieved after 2nd round	242
Table 4. 10	Qualitative comments of experts	244
Table 5. 1	Comparison qualitative vs quantitative methods (adopted from (Bryman, 2012) page, 36)	258
Table 5. 2	Interview duration of the key informants	270
Table 5. 3	Demographics of the key informants	272
Table 5. 4	Field/ area of expertise and professional associations or affiliations of key informants	273

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
Figure 2. 1	Types of medication reviews and their clinical characteristic (Bulajeva et al., 2014)	80
Figure 3. 1	PRISMA flow diagram	127
Figure 3. 2	Risk of bias (RoB) Cochrane graph	129
Figure 3. 3	Risk of bias (RoB) Cochrane summary	130
Figure 3. 4	Effective Practice and Organization of Care (EPOC) graph	130
Figure 3. 5	Effective Practice and Organization of Care (EPOC) summary	131
Figure 3. 6	Narrative synthesis of the outcomes in the included studies	132
Figure 4. 1	The Delphi process	188
Figure 4. 2	Expert selection flowchart (modified from (Okoli & Pawlowski, 2004))	195
Figure 4. 3	Geographical diversity of Delphi experts in this study across Malaysia	214
Figure 4. 4	Statements of 1st and 2nd round	220
Figure 4. 5	Number of ranking statements	221
Figure 4. 6	The proposed Collaborative Medication Therapy Management model	254
Figure 5. 1	Geographical diversity of key informants across Malaysia	271
Figure 5. 2	Tree map depicting the coverage of five themes	275
Figure 5. 3	Developed countries and Malaysia; a comparison	276
Figure 5. 4	Current situation in Malaysia	278
Figure 5. 5	Collaboration of community pharmacist and general practitioner in Malaysia	294
Figure 5. 6	Dispensing separation in Malaysia	300

Figure 5. 7	Way forward towards the collaboration of community pharmacist and general practitioner in Malaysia for Collaborative Medication Therapy Management model	304
Figure 5. 8	Comparison of current situation and way forward for Collaborative Medication Therapy Management	322
Figure 5. 9	Concept mapping of way forward towards Collaborative Medication Therapy Management model in Malaysia	330

ABBREVIATIONS

ACQ	Asthma Control Questionnaire
ACT	Asthma Control Test
AIDS	Acquired Immune Deficiency Syndrome
AKQ	Asthma Knowledge Questionnaire
AQLQ	Asthma Quality of Life Questionnaire
BMQ	Brief Medication Questionnaire
CAKQ	Consumer Asthma Knowledge Questionnaire
CC	Case Control
Cont. I	Controlled Interventions
CMTM	Collaborative Medication Therapy Management
COPD	Chronic Obstructive Pulmonary Disease
CP	Community Pharmacist
CPA	Canadian Pharmacist Association
CPGM	Community Pharmacy Guild Malaysia
C-RCT	Clustered Randomized Control Trials
CT	Controlled Trials
CVDs	Cardiovascular Diseases
CVI	Content Validity Index
DRPs	Drug Related Problems
DUR	Drug Utilization Review
EPOC	Effective Practice and Organization of Care
ES	Effect Size
FEV1	Forced Expiratory Volume
FIP	International Pharmaceutical Federation
FMS	Family Medicine Specialist
FVC	Forced Vital Capacity
GAR	Global Asthma Report
GINA	Global Initiative for Asthma
GP	General Practitioner
HMR	Home Medication Review
ICC	Intra-class Correlation Coefficient
IIUM	International Islamic University of Malaysia
IPC	Inter-professional Collaboration
IQR	Interquartile Range
KI	Key Informant
LABA	Long acting Beta Agonist
LWAQ	Living with Asthma Questionnaire
MeSH	Medical Subject Handling
MHE	Ministry of Higher Education
MMA	Malaysian Medical Association
MoH	Ministry of Health
MPS	Malaysian Pharmaceutical Society
MTM	Medication Therapy Management
MUR	Medication Use Review
NCDs	Non-communicable Diseases

P to R ratio	Preventer to Reliever ratio
PCAQ	Perceived Control of Asthma Questionnaire
PEFR	Peak Expiratory Flow Rate
QoL	Quality of Life
QP	QuestionPro
RCT	Randomized Controlled Trial
RevMan	Review Manager
RMMR	Residential Medication Management Review
RoB	Risk of Bias
SABA	Short acting beta agonist
SPSS	Statistical Package for Social Sciences
UHC	Universal Health Coverage
UK	United Kingdom
USA or US	United States of America
WHO	World Health Organization

CHAPTER ONE

INTRODUCTION

1.1 CHAPTER INTRODUCTION

This chapter starts with the introduction and background of the research problem. It takes an account of global burden and problems in medicine management in chronic diseases. It highlights the concept and need of collaboration among healthcare professionals to manage chronic disease in an effective way. Then, chapter discusses in detail the Malaysian healthcare system, growing burden of chronic diseases, and prevalence of irrational prescribing and medicine use, especially in private primary care in Malaysia to establish the problem statement and gaps in practice and policy. This follows setting research objectives guided by specific research questions. At the end, it highlights the significance of the study and introduces the readers to the chapter wise organization of thesis in accordance with the research objective set.

1.2 BACKGROUND OF THE PROBLEM

1.2.1 Global Burden of Chronic Diseases

Chronic diseases also known as non-communicable diseases or lifestyle-related diseases, impose a serious public health issue all around the globe. World Health Organization (WHO) define a chronic disease as "diseases which are not passed from person to person, they are of long duration and generally slow progression.". WHO has prime focus on the four major chronic diseases based on prevalence and magnitude of threat, these are: cardiovascular diseases, cancer, chronic respiratory diseases (asthma and chronic obstructive pulmonary diseases) and diabetes. In almost every country, chronic diseases are leading cause of death and disease burden (Bernell & Howard, 2016; Sinha & Pati, 2017; WHO, 2014a). For the sake of clarity, and to distinguish chronic diseases from acute conditions which are curable, throughout this thesis the term chronic diseases would refer to incurable diseases which require prolong treatment and care or lifelong treatment and care.

In 2016, 41 million deaths were attributed to chronic diseases, which was 71% of total deaths per annum around the globe. A common myth is, chronic diseases related deaths occur only in older people, in fact, 86% burden of chronic diseases manifest itself between 30 to 69 years of age range (WHO, 2018b).

In 21st century, chronic diseases are considered as one of the grave threats to healthcare systems because of human miseries, hardships and the damage they levy on the economic fabric of countries. This is more relevant for low- and middle-income countries which share 85% of chronic diseases' burden of the globe (WHO, 2018a).

Chronic diseases require life-long medications and continuous care, thus persistently consume large proportion of healthcare resources which result in constant overload not only on the budget of an individual or family, but also on the overall health

budget of a country. The growing threat of chronic diseases thus occults the economic development and is considered an under-appreciated cause of poverty in these countries. Fact is, economic ramifications of chronic diseases have already been felt around the world, but these ramifications are more disastrous for low- and middle-income countries. Reduction in the burden of chronic diseases is not only a cardinal priority, but also a paramount step in the sustainable development of a country (WHO, 2013b, 2014a).

No country in the world can afford to ignore the up-surgng burden of chronic diseases. If countries do not opt for an evidence based systematic intervention and action, the cost of health in chronic diseases would keep on mounting till it gets out of the capacity of a country (Sinha & Pati, 2017; WHO, 2014b). Thus, there is a need of systematic approach in chronic diseases management with a focus on treatment plans which ensure patients' adherence to the prescribed therapy, improve patient safety and maximize positive health outcomes. These approaches are largely dependent on the local healthcare policies made by the government under guidance and influence of various healthcare stakeholders. A healthcare system, if enabled based on effective policies, may reciprocate the needs of people with chronic diseases and proffer significant reduction of these premature deaths which were largely preventable (WHO, 2013b). So, it is imperative to focus, foresee and deploy serious steps to manage the growing burden of chronic diseases. In this regard, the essential step is to open a liberal communication channel between healthcare professionals. To effectively address the major challenge imposed by chronic diseases, "WHO Global Action Plan for the Non-Communicable diseases 2013-2020" emphasizes more on strengthening of the healthcare systems through policies which foster a culture of collaborative care practice involving all healthcare stakeholders, and making them responsible for prevention,

control and management of chronic diseases (Morrissey, Ball, Jackson, Pilloto, & Nielsen, 2015; WHO, 2013b).

1.2.2 Medicines and Chronic Diseases

1.2.2.1 Medicine Use in Chronic Diseases

Medicines have been part and parcel of human society. They are used to cure, maintain health, prevent illness and manage chronic diseases. However, in case of chronic diseases, medicines receive the vital importance and play a crucial role because they are the most common, repeated and continual interventions which must be applied throughout life (Perez-Jover et al., 2018). For instance, in USA alone, data from centre of disease control and preventions reveals, 50% of the USA population uses at least one prescription drug in a month and 10% population takes more than 5 medicines at a time (Blozik, Rapold, & Reich, 2015). Similarly, in New Zealand , older population take on an average of 7 medications per day (Merry & Webster, 2008; Robb, Loe, Maharaj, Hamblin, & Seddon, 2017). The aging, multimorbid population with chronic diseases is dilating globally. Thus, management of chronic diseases is heavily dependent on the appropriate use of medicines. Furthermore, one out of ten most common reasons of healthcare system inefficiency is spending too much on medicines which are being inappropriately used. Nevertheless, if used appropriately, medicines give sustainable positive results (WHO, 2015).

1.2.2.2 Medication Errors and Adverse Drug Reactions

Another important aspect of medicine use process involves potential medication errors, which may have originated from errors in prescribing, dispensing, wrong storage,